Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Change in Account Payables came in at $549000.0 in Q1 2026, up 240.99% year-on-year from $161000.0 in Q1 2025, and up 125.44% quarter-over-quarter from -$2.2 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Change in Account Payables history runs 7 years deep, the most recent figure standing at $549000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 240.99% year-over-year to $549000.0 in Q1 2026; TTM through Mar 2026 was -$662000.0, a 192.72% decrease from a year earlier, with the FY2025 full-year figure at -$1.0 million, down 247.68% from the prior year.
- Change in Account Payables rose to $549000.0 in Q1 2026 per RANI's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.1 million in Q3 2024 and bottomed at -$2.2 million in Q4 2025.
- The 5-year median for Change in Account Payables is $131000.0 (2022), against an average of -$13058.8.
- Across the five-year window, Change in Account Payables jumped 263.89% in 2022 and slumped 942.51% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at -$214000.0 in 2022, then plunged by 209.81% to -$663000.0 in 2023, then jumped by 68.78% to -$207000.0 in 2024, then slumped by 942.51% to -$2.2 million in 2025, then jumped by 125.44% to $549000.0 in 2026.
- Per Business Quant, the three latest RANI Change in Account Payables figures stand at $549000.0 (Q1 2026), -$2.2 million (Q4 2025), and $669000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | 549,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 549,000.00 |
| Mar 31, 2026 | 549,000.00 |
| Dec 31, 2025 | -2.16 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | 669,000.00 |
| Sep 30, 2025 | 669,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Sep 30, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | -300,000.00 |
| Jun 30, 2024 | -300,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Dec 31, 2023 | -663,000.00 |
| Dec 31, 2023 | -663,000.00 |